ET on whoY makes a nice summary .....
For me it was excellent because there has been-more clarity on FDA
- approval process-strong indication that an approval for aGvHD will occur in second half
-cost control, with cash burn less than forecast $US12m per Q, and less to be spent on adult aGvHD trial
- go for label extension instead $10m debt paydown and a consequent- reduction of $10m of the amount of cash required to be held aginst this debt
- so no impact on the spendable cash position cash position comfortable until approval in H2 2024moves to strengthen the Board position of GG via his representativetrials
and FDA meetings happening without slippage at present.
Whether the price moves up or down on any given day doesn't change these positive outcomes.
ET on whoY makes a nice summary .....For me it was excellent...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.050(4.65%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.13 | $1.07 | $5.964M | 5.444M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25000 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 176236 | 7 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
0.050 ( 4.69 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.13 | $1.07 | 829227 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| MSB (ASX) Chart |